• 文献标题:   3D Label-Free Matrix Metalloproteinase-3 Immunosensor Based on Graphene Oxide/Polypyrrole-Ionic Liquid Nanocomposite
  • 文献类型:   Article
  • 作  者:   YIN ZY, WANG YY, ZHENG TT, ZHANG R, LI XH, ZHU JJ, CHEN XJ
  • 作者关键词:   labelfree immunosensor, 3d nanostructure, graphene oxide, polypyrrole, ionic liquid, matrix metalloproteinase3
  • 出版物名称:   SCIENCE OF ADVANCED MATERIALS
  • ISSN:   1947-2935 EI 1947-2943
  • 通讯作者地址:   Nanjing Univ
  • 被引频次:   4
  • DOI:   10.1166/sam.2015.2290
  • 出版年:   2015

▎ 摘  要

Matrix metalloproteinase-3 (MMP-3) is a proteinase involved in the degradation of the extracellular matrix and it potentially plays an important role in metastasis development during the early stage of invasive cancers. In this work, a label-free electrochemical impedance immunosensor is for the first time developed for highly sensitive determination of MMP-3 based on the covalent immobilization of MMP-3 antibody on a 3D graphene oxide/polypyrrole-ionic liquid (GO/PPy-IL) composite film. The 3D GO/PPy-IL film was constructed by one-step electro-deposition of GO/PPy in 1-Butyl-3-methylimidazolium tetrafluoroborate (BMIm(+)BF(4)(-)) onto a silica opal template modified indium tin oxide (ITO) electrode, and showed high surface area, good biocompatibility and enhanced electronic conductivity. The MMP-3 concentration is measured through the relative increase of impedance values in corresponding specific conjugation of MMP-3 antigen with the MMP-3 antibody. Under the optimal conditions, the relative increased impedance values are proportional to the logarithmic value of MMP-3 concentrations in a linear range of 1 to 1000 pg . mL(-1) with a low detection limit of 1 pg . mL(-1). In comparison with current enzyme-linked immunosorbent assay, the MMP-3 immunosensor shows wider linear range, lower detection limit and simpler manipulation. Moreover, the immunosensor exhibits excellent selectivity, good stability, satisfactory reproducibility and regeneration. Such a 3D GO/PPy-IL film could have widespread applications in clinical screening of cancer biomarkers for point-of-care diagnosis.